The changing circumstance of atrial fibrillation - progress towards precision medicine

Journal of Internal Medicine

Volumn 279, Issue 5, 2016, Pages 412-427

  Camm, A J ^a   Savelieva, I ^a   Potpara, T ^b   Hindriks, G ^c   Pison, L ^d   Blomstrom Lundqvist C ^e  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^b UNIVERSITY OF BELGRADE   (Serbia)

^c UNIVERSITY OF LEIPZIG HEART CENTER   (Germany)

^d MAASTRICHT UNIVERSITY   (Netherlands)

^e UPPSALA UNIVERSITY   (Sweden)

Author keywords

Atrial fibrillation; Biomarkers; Epidemiology; Mechanism; Outcome; Risk factors

Indexed keywords

BIOLOGICAL MARKER;

ATRIAL FIBRILLATION; ENDURANCE SPORT; HUMAN; KIDNEY DYSFUNCTION; META ANALYSIS (TOPIC); METABOLOMICS; NONHUMAN; OBESITY; OUTCOME ASSESSMENT; PERSONALIZED MEDICINE; PREDICTION; PRIORITY JOURNAL; PROTEOMICS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; SCREENING; SLEEP DISORDERED BREATHING; ADULT; AGED; BLOOD; COMPLICATION; COST OF ILLNESS; EARLY DIAGNOSIS; FEMALE; INCIDENCE; MALE; MIDDLE AGED; PREVALENCE; PROGNOSIS; RECURRENT DISEASE; TRENDS;

ADULT; AGED; ATRIAL FIBRILLATION; BIOMARKERS; COST OF ILLNESS; EARLY DIAGNOSIS; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; OBESITY; PRECISION MEDICINE; PREVALENCE; PROGNOSIS; RECURRENCE; RISK FACTORS; SLEEP APNEA SYNDROMES;

EID: 84963628410     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/joim.12478     Document Type: Review

References (117)

1. Chugh SS, Havmoeller R, Narayanan K et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation 2014; 129: 837-47.
2. Krijthe BP, Kunst A, Benjamin EJ et al. Projections on the number of individuals with atrial fibrillation in the European Union, from 2000 to 2060. Eur Heart J 2013; 34: 2746-51.
3. Heeringa J, van der Kuip DA, Hofman A et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J 2006; 27: 949-53.
4. Lloyd-Jones DM, Wang TJ, Leip EP et al. Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. Circulation 2004; 110: 1042-6.
5. Stefansdottir H, Aspelund T, Gudnason V, Arnar DO. Trends in the incidence and prevalence of atrial fibrillation in Iceland and future projections. Europace 2011; 13: 1110-7.
6. Lip GY, Brechin CM, Lane DA. The global burden of atrial fibrillation and stroke: a systematic review of the epidemiology of atrial fibrillation in regions outside North America and Europe. Chest 2012; 142: 1489-98.
7. Guo Y, Tian Y, Wang H et al. Prevalence, incidence, and lifetime risk of atrial fibrillation in China: new insights into the global burden of atrial fibrillation. Chest 2015; 147: 109-19.
8. Shantsila E, Wolff A, Lip GY, Lane DA. Optimising stroke prevention in patients with atrial fibrillation: application of the GRASP-AF audit tool in a UK general practice cohort. Br J Gen Pract 2015; 65: e16-23.
9. Global Burden of Disease Study 2013 Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2015; 386: 743-800.
10. Kannel WB, Benjamin EJ. Status of the epidemiology of atrial fibrillation. Med Clin North Am 2008; 92: 17-40, ix.
11. Andersson P, Löndahl M, Abdon NJ, Terent A. The prevalence of atrial fibrillation in a geographically well-defined population in northern Sweden: implications for anticoagulation prophylaxis. J Intern Med 2012; 272: 170-6.
12. Borzecki AM, Bridgers DK, Liebschutz JM et al. Racial differences in the prevalence of atrial fibrillation among males. J Natl Med Assoc 2008; 100: 237-45.
13. Dewland TA, Olgin JE, Vittinghoff E, Marcus GM. Incident atrial fibrillation among Asians, Hispanics, blacks, and whites. Circulation 2013; 128: 2470-7.
14. Chao TF, Liu CJ, Wang KL, et al. Should atrial fibrillation patients with 1 additional risk factor of the CHA2DS2-VASc score (beyond sex) receive oral anticoagulation? J Am Coll Cardiol 2015; 65: 635-42.
15. Miyasaka Y, Barnes ME, Gersh BJ et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation 2006; 114: 119-25.
16. Heemstra HE, Nieuwlaat R, Meijboom M, Crijns HJ. The burden of atrial fibrillation in the Netherlands. Neth Heart J 2011; 19: 373-8.
17. Savelieva I, Camm AJ. Clinical relevance of silent atrial fibrillation: prevalence, prognosis, quality of life, and management. J Interv Card Electrophysiol 2000; 4: 369-82.
18. Furberg CD, Psaty BM, Manolio TA et al. Prevalence of atrial fibrillation in elderly subjects (the Cardiovascular Health Study). Am J Cardiol 1994; 74: 236-41.
19. Glotzer TV, Daoud EG, Wyse DG et al. The relationship between daily atrial tachyarrhythmia burden from implantable device diagnostics and stroke risk: the TRENDS study. Circ Arrhythm Electrophysiol 2009; 2: 474-80.
20. Healey JS, Connolly SJ, Gold MR et al. Subclinical atrial fibrillation and the risk of stroke. N Engl J Med 2012; 366: 120-9.
21. Sanna T, Diener HC, Passman RS et al. Cryptogenic stroke and underlying atrial fibrillation. N Engl J Med 2014; 370: 2478-86.
22. Friberg L, Engdahl J, Frykman V et al. Population screening of 75- and 76-year-old men and women for silent atrial fibrillation (STROKESTOP). Europace 2013; 15: 135-40.
23. Svennberg E, Engdahl J, Al-Khalili F et al. Mass screening for untreated atrial fibrillation: the STROKESTOP Study. Circulation 2015; 131: 2176-84.
24. Lowres N, Neubeck L, Salkeld G et al. Feasibility and cost-effectiveness of stroke prevention through community screening for atrial fibrillation using iPhone ECG in pharmacies. The SEARCH-AF study. Thromb Haemost 2014; 111: 1167-76.
25. Aronsson M, Svennberg E, Rosenqvist M et al. Cost-effectiveness of mass screening for untreated atrial fibrillation using intermittent ECG recording. Europace 2015; 17: 1023-9.
26. Benjamin EJ, Levy D, Vaziri SM et al. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA 1994; 271: 840-4.
27. Zubaid M, Rashed WA, Alsheikh-Ali AA et al. Management and 1-year outcomes of patients with atrial fibrillation in the Middle East: Gulf Survey of Atrial Fibrillation Events (Gulf SAFE) Investigators. Angiology 2015; 66: 464-71.
28. Chamberlain AM, Agarwal SK, Ambrose M et al. Metabolic syndrome and incidence of atrial fibrillation among blacks and whites in the Atherosclerosis Risk in Communities (ARIC) Study. Am Heart J 2010; 159: 850-6.
29. Tedrow UB, Conen D, Ridker PM et al. The long- and short-term impact of elevated body mass index on the risk of new atrial fibrillation the WHS (women's health study). J Am Coll Cardiol 2010; 55: 2319-27.
30. Karasoy D, Bo Jensen T, Hansen ML et al. Obesity is a risk factor for atrial fibrillation among fertile young women: a nationwide cohort study. Europace 2013; 15: 781-6.
31. Kanagala R, Murali NS, Friedman PA et al. Obstructive sleep apnea and the recurrence of atrial fibrillation. Circulation 2003; 107: 2589-94.
32. Myrstad M, Løchen ML, Graff-Iversen S et al. Increased risk of atrial fibrillation among elderly Norwegian men with a history of long-term endurance sport practice. Scand J Med Sci Sports 2014; 24: e238-44.
33. Mont L, Elosua R, Brugada J. Endurance sport practice as a risk factor for atrial fibrillation and atrial flutter. Europace 2009; 11: 11-7.
34. Abrahamsen B, Eiken P, Brixen K. Atrial fibrillation in fracture patients treated with oral bisphosphonates. J Intern Med 2009; 265: 581-92.
35. Martin RI, Pogoryelova O, Koref MS, Bourke JP, Teare MD, Keavney BD. Atrial fibrillation associated with ivabradine treatment: meta-analysis of randomised controlled trials. Heart 2014 Oct; 100: 1506-10.
36. Tsang TS, Gersh BJ, Appleton CP et al. Left ventricular diastolic dysfunction as a predictor of the first diagnosed nonvalvular atrial fibrillation in 840 elderly men and women. J Am Coll Cardiol 2002; 40: 1636-44.
37. Wyse DG, Van Gelder IC, Ellinor PT et al. Lone atrial fibrillation: does it exist? J Am Coll Cardiol 2014; 63: 1715-23.
38. Calvo N, Ramos P, Montserrat S et al. Emerging risk factors and the dose-response relationship between physical activity and lone atrial fibrillation: a prospective case-control study. Europace 2015; pii: euv216 [Epub ahead of print].
39. Kopecky SL, Gersh BJ, McGoon MD et al. The natural history of lone atrial fibrillation. A population-based study over three decades. N Engl J Med 1987; 317: 669-74.
40. Brand FN, Abbott RD, Kannel WB, Wolf PA. Characteristics and prognosis of lone atrial fibrillation. 30-year follow-up in the Framingham Study. JAMA 1985; 254: 3449-53.
41. Potpara T, Stankovic GR, Beleslinet BD. Al. A 12-year follow-up study of patients with newly diagnosed lone atrial fibrillation Implications of arrhythmia progression on prognosis: the Belgrade atrial fibrillation study. Chest 2012; 141: 339-47.
42. Weijs B, Pisters R, Haest RJ et al. Patients originally diagnosed with idiopathic atrial fibrillation more often suffer from insidious coronary artery disease compared to healthy sinus rhythm controls. Heart Rhythm 2012; 9: 1923-9.
43. Osranek M, Bursi F, Bailey KR et al. Left atrial volume predicts cardiovascular events in patients originally diagnosed with lone atrial fibrillation: three-decade follow-up. Eur Heart J 2005; 26: 2556-61.
44. Fredersdorf S, Ucer E, Jungbauer C et al. Lone atrial fibrillation as a positive predictor of left atrial volume reduction following ablation of atrial fibrillation. Europace 2014; 16: 26-32.
45. Pison L, Hocini M, Potpara TS et al. Work-up and management of lone atrial fibrillation: results of the European Heart Rhythm Association Survey. Europace 2014; 16: 1521-3.
46. Grimsmo J, Grundvold I, Maehlum S, Arnesen H. High prevalence of atrial fibrillation in long-term endurance cross-country skiers: echocardiographic findings and possible predictors - a 28-30 years follow-up study. Eur J Cardiovasc Prev Rehabil 2010; 17: 100-5.
47. Abdulla J, Nielsen JR. Is the risk of atrial fibrillation higher in athletes than in the general population? A systematic review and meta-analysis Europace 2009; 11: 1156-9.
48. Mozaffarian D, Furberg CD, Psaty BM, Siscovick D. Physical activity and incidence of atrial fibrillation in older adults: the cardiovascular health study. Circulation 2008; 118: 800-7.
49. Wilhelm M, Roten L, Tanner H et al. Atrial remodeling, autonomic tone, and lifetime training hours in nonelite athletes. Am J Cardiol 2011; 108: 580-5.
50. Delise P, Allocca G, Sitta N et al. Pathophysiology of atrioventricular conduction disturbances in sports practitioners. G Ital Cardiol (Rome) 2012; 13(Suppl 2): 118S-22S.
51. Camm AJ, Kirchhof P, Lip GY et al. Guidelines for the management of atrial fibrillation: the task force for the management of atrial fibrillation of the European Society of Cardiology (ESC). Europace 2010; 12: 1360-420.
52. Wang TJ, Parise H, Levy D et al. Obesity and the risk of 920 new-onset atrial fibrillation. JAMA 2004; 292: 2471-7.
53. Frost L, Benjamin EJ, Fenger-Grøn M, Pedersen A, Tjønneland A, Overvad K. Body fat, body fat 932 distribution, lean body mass and atrial fibrillation and flutter. A Danish cohort study. Obesity (Silver Spring) 2014; 22: 1546-52.
54. Vermond RA, Geelhoed B, Verweij N et al. Incidence 922 of atrial fibrillation and relation with cardiovascular events, heart failure and mortality - a 923 community-based study from the Netherlands. J Am Coll Cardiol 2015; 66: 1000-7.
55. Wong CX, Sullivan T, Sun MT et al. Obesity and the risk of incident, post-operative, and post-ablation atrial fibrillation: a meta-analysis of 626, 603 individuals in 51 studies. JACC Clin Electrophysiol 2015; 1: 139-52.
56. Thanassoulis G, Massaro JM, O'Donnell CJ et al. Pericardial fat is associated with prevalent atrial fibrillation: the Framingham heart study. Circ Arrhythm Electrophysiol 2010; 3: 345-50.
57. Munger TM, Dong YX, Masaki M et al. Electrophysiological and hemodynamic characteristics associated with obesity in patients with atrial fibrillation. J Am Coll Cardiol 2012; 60: 851-60.
58. Abed HS, Wittert GA, Leong DP et al. Effect of weight reduction and cardiometabolic risk factor management on symptom burden and severity in patients with atrial fibrillation: a randomized clinical trial. JAMA 2013; 310: 2050-60.
59. Pathak RK, Middeldorp ME, Meredith M et al. Long-term effect of goal-directed weight management in an atrial fibrillation cohort: a long-term follow-918 up study (LEGACY). J Am Coll Cardiol 2015; 65: 2159-69.
60. Pathak RK, Elliott A, Middeldorp ME et al. Impact of CARDIOrespiratory FITness on Arrhythmia Recurrence in Obese Individuals with Atrial Fibrillation: the CARDIO-FIT study. J Am Coll Cardiol 2015; 66: 985-96.
61. Gami AS, Hodge DO, Herges RM et al. Obstructive sleep apnea, 1035 obesity, and the risk of incident atrial fibrillation. J Am Coll Cardiol 2007; 49: 565-71.
62. Li L, Wang ZW, Li J et al. Efficacy of catheter ablation of atrial fibrillation in patients with obstructive sleep apnoea with and without continuous positive airway pressure treatment: a meta-analysis of observational studies. Europace 2014; 16: 1309-14.
63. Oldgren J, Healey JS, Ezekowitz M et al. Variations in cause and management of atrial fibrillation in a prospective registry of 15, 400 emergency department patients in 46 countries: the RE-LY Atrial Fibrillation Registry. Circulation 2014; 129: 1568-76.
64. Chen LY, Sotoodehnia N, Bůžková P et al. Atrial fibrillation and the risk of sudden cardiac death: the atherosclerosis risk in communities study and cardiovascular health study. JAMA Intern Med 2013; 173: 29-35.
65. Nattel S, Guasch E, Savelieva I et al. Early management of atrial fibrillation to prevent cardiovascular complications. Eur Heart J 2014; 7: 1448-56.
66. Savelieva I, Kakouros N, Kourliouros A, Camm AJ. Upstream therapies for management of atrial fibrillation: review of clinical evidence and implications for European Society of Cardiology guidelines. Part I: primary prevention. Europace 2011; 13: 308-28.
67. Savelieva I, Kakouros N, Kourliouros A, Camm AJ. Upstream therapies for management of atrial fibrillation: review of clinical evidence and implications for European Society of Cardiology guidelines. Part II: secondary prevention. Europace 2011; 13: 610-25.
68. Aviles RJ, Martin DO, Apperson-Hansen C et al. Inflammation as a risk factor for atrial fibrillation. Circulation 2003; 108: 3006-10.
69. Marcus GM, Whooley MA, Glidden DV et al. Interleukin-6 and atrial fibrillation in patients with coronary artery disease: data from the Heart and Soul Study. Am Heart J 2008; 155: 303-9.
70. Latini R, Masson S, Pirelli S, et al. Circulating cardiovascular biomarkers in recurrent atrial fibrillation: data from the GISSI-atrial fibrillation trial. J Intern Med 2011; 269: 160-71.
71. Patton KK, Ellinor PT, Heckbert SR et al. N-terminal pro-B-type natriuretic peptide is a major predictor of the development of atrial fibrillation: the Cardiovascular Health Study. Circulation 2009; 120: 1768-74.
72. Huxley RR, Lopez FL, MacLehose RF et al. Novel association between plasma matrix metalloproteinase-9 and risk of incident atrial fibrillation in a case-cohort study: the Atherosclerosis Risk in Communities study. PLoS One 2013; 8: e59052.
73. Schnabel RB, Larson MG, Yamamoto JF et al. Relations of biomarkers of distinct pathophysiological pathways and atrial fibrillation incidence in the community. Circulation 2010; 121: 200-7.
74. Sinner MF, Stepas KA, Moser CB et al. B-type natriuretic peptide and C-reactive protein in the prediction of atrial fibrillation risk: the CHARGE-AF Consortium of community-based cohort studies. Europace 2014; 16: 1426-33.
75. Schnabel RB, Wild PS, Wilde S et al. Multiple biomarkers and atrial fibrillation in the general population. PLoS One 2014; 17: e112486.
76. Pathak RK, Abhayaratna WP, Mehta A, Lau D, Alasady M, Sanders P. Biomarkers and recurrence of atrial fibrillation after successful cardioversion: results of a meta-analysis. Circulation 2012; 126: A18339.
77. Zografos T, Maniotis C, Katsivas A, Katritsis D. Relationship between brain natriuretic peptides and recurrence of atrial fibrillation after successful direct current cardioversion: a meta-analysis. Pacing Clin Electrophysiol 2014; 37: 1530-7.
78. Govindan M, Borgulya G, Kiotsekoglou A et al. Prognostic value of left atrial expansion index and exercise-induced change in atrial natriuretic peptide as long-term predictors of atrial fibrillation recurrence. Europace 2012; 14: 1302-10.
79. Kirchhof P, Lip GY, Van Gelder IC et al. Comprehensive risk reduction in patients with atrial fibrillation: emerging diagnostic and therapeutic options-a report from the 3rd Atrial Fibrillation Competence NETwork/European Heart Rhythm Association consensus conference. Europace 2012; 14: 8-27.
80. Yo CH, Lee SH, Chang SS et al. Value of high-sensitivity C-reactive protein assays in predicting atrial fibrillation recurrence: a systematic review and meta-analysis. BMJ Open 2014; 4: e004418.
81. Jiang Z, Dai L, Song Z, Li H, Shu M. Association between C-reactive protein and atrial fibrillation recurrence after catheter ablation: a meta-analysis. Clin Cardiol 2013; 36: 548-54.
82. Savelieva I, Bajpai A, Camm AJ. Stroke in atrial fibrillation: update on pathophysiology, new antithrombotic therapies, and evolution of procedures and devices. Ann Med 2007; 39: 371-91.
83. Wannamethee SG, Whincup PH, Lennon L et al. Fibrin D-dimer, tissue-type plasminogen activator, von Willebrand factor, and risk of incident stroke in older men. Stroke 2012; 43: 1206-11.
84. Conway DS, Pearce LA, Chin BS et al. Prognostic value of plasma von Willebrand factor and soluble P-selectin as indices of endothelial damage and platelet activation in 994 patients with nonvalvular atrial fibrillation. Circulation 2003; 107: 3141-5.
85. Krishnamoorthy S, Khoo CW, Lim HS et al. Prognostic role of plasma von Willebrand factor and soluble E-selectin levels for future cardiovascular events in a 'real-world' community cohort of patients with atrial fibrillation. Eur J Clin Invest 2013; 43: 1032-8.
86. Sadanaga T, Sadanaga M, Ogawa S. Evidence that D-dimer levels predict subsequent thromboembolic and cardiovascular events in patients with atrial fibrillation during oral anticoagulant therapy. J Am Coll Cardiol 2010; 55: 2225-31.
87. Fu R, Wu S, Wu P, Qiu J. A study of blood soluble P-selectin, fibrinogen, and von Willebrand factor levels in idiopathic and lone atrial fibrillation. Europace 2011; 13: 31-6.
88. Hijazi Z, Oldgren J, Siegbahn A et al. Biomarkers in atrial fibrillation: a clinical review. Eur Heart J 2013; 34: 1475-80.
89. Hijazi Z, Oldgren J, Andersson U et al. Cardiac biomarkers are associated with an increased risk of stroke and death in patients with atrial fibrillation: a Randomized Evaluation of Long-term Anticoagulation Therapy (RE-LY) substudy. Circulation 2012; 125: 1605-16.
90. Hijazi Z, Siegbahn A, Andersson U et al. High-sensitivity troponin I for risk assessment in patients with atrial fibrillation: insights from the Apixaban for Reduction in Stroke and other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. Circulation 2014; 129: 625-34.
91. Hijazi Z, Siegbahn A, Andersson U et al. Comparison of cardiac troponins I and T measured with high-sensitivity methods for evaluation of prognosis in atrial fibrillation: an ARISTOTLE substudy. Clin Chem 2015; 61: 368-78.
92. Hijazi Z, Wallentin L, Siegbahn A et al. N-terminal pro-B-type natriuretic peptide for risk assessment in patients with atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation). J Am Coll Cardiol 2013; 61: 2274-84.
93. Shibazaki K, Kimura K, Fujii S et al. Brain natriuretic peptide levels as a predictor for new atrial fibrillation during hospitalization in patients with acute ischemic stroke. Am J Cardiol 2012; 109: 1303-7.
94. Aulin J, Siegbahn A, Hijazi Z et al. Interleukin-6 and C-reactive protein and risk for death and cardiovascular events in patients with atrial fibrillation. Am Heart J 2015; 170: 1151-60.
95. Wallentin L, Hijazi Z, Andersson U et al. Growth differentiation factor 15, a marker of oxidative stress and inflammation, for risk assessment in patients with atrial fibrillation: insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. Circulation 2014; 130: 1847-58.
96. Boriani G, Savelieva I, Dan GA et al. Chronic kidney disease in patients with cardiac rhythm disturbances or implantable electrical devices: clinical significance and implications for decision making-a position paper of the European Heart Rhythm Association endorsed by the Heart Rhythm Society and the Asia Pacific Heart Rhythm Society. Europace 2015; 17: 1169-96.
97. Go AS, Fang MC, Udaltsova N et al. Impact of proteinuria and glomerular filtration rate on risk of thromboembolism in atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Circulation 2009; 119: 1363-9.
98. Olesen JB, Lip GY, Kamper AL et al. Stroke and bleeding in atrial fibrillation with chronic kidney disease. N Engl J Med 2012; 367: 625-35.
99. Hohnloser SH, Hijazi Z, Thomas L et al. Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial. Eur Heart J 2012; 33: 2821-30.
100. Hijazi Z, Hohnloser SH, Oldgren J et al. Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) trial analysis. Circulation 2014; 129: 961-70.
101. Camm AJ, Savelieva I. "R" for "renal" and for "risk": refining risk stratification for stroke in atrial fibrillation. Circulation 2013; 127: 169-71.
102. Piccini JP, Stevens SR, Chang YC et al. Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R2CHADS2 index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors In Atrial fibrillation) Study Cohorts. Circulation 2013; 127: 224-32.
103. Singer DE, Chang Y, Borowsky LH et al. A new risk scheme to predict ischemic stroke and other thromboembolism in atrial fibrillation: the ATRIA study stroke risk score. J Am Heart Assoc 2013; 2: e000250.
104. Mathew JS, Sachs MC, Katz R et al. Fibroblast growth factor-23 and incident atrial fibrillation: the Multi-Ethnic Study of Atherosclerosis (MESA) and the Cardiovascular Health Study (CHS). Circulation 2014; 130: 298-307.
105. Alonso A, Misialek JR, Eckfeldt JH et al. Circulating fibroblast growth factor-23 and the incidence of atrial fibrillation: the Atherosclerosis Risk in Communities study. J Am Heart Assoc 2014; 3: e001082.
106. Lippi G, Cervellin G, Sanchis-Gomar F. Galectin-3 in atrial fibrillation: simple bystander, player or both? Clin Biochem 2015; 48: 818-22.
107. Ho JE, Yin X, Levy D et al. Galectin 3 and incident atrial fibrillation in the community. Am Heart J 2014; 167: 729-34.
108. Wu XY, Li SN, Wen SN et al. Plasma galectin-3 predicts clinical outcomes after catheter ablation in persistent atrial fibrillation patients without structural heart disease. Europace 2015; 17: 1541-7.
109. Kornej J, Schmidl J, Ueberham L et al. Galectin-3 in patients with atrial fibrillation undergoing radiofrequency catheter ablation. PLoS One 2015; 10: e0123574.
110. Macheret F, Bartz TM, Djousse L et al. Higher circulating adiponectin levels are associated with increased risk of atrial fibrillation in older adults. Heart 2015; 101: 1368-74.
111. De Souza AI, Camm AJ. Proteomics of atrial fibrillation. Circ Arrhythm Electrophysiol 2012; 5: 1036-43.
112. Alonso A, Yu B, Qureshi WT et al. Metabolomics and incidence of atrial fibrillation in African Americans: the Atherosclerosis Risk in Communities (ARIC) Study. PLoS One 2015; 10: e0142610.
113. Lanters EA, van Marion DM, Steen H, de Groot NM, Brundel BJ. The future of atrial fibrillation therapy: intervention on heat shock proteins influencing electropathology is the next in line. Neth Heart J 2015; 23: 327-33.
114. Camm AJ, Al-Khatib SM, Calkins H et al. A proposal for new clinical concepts in the management of atrial fibrillation. Am Heart J 2012; 164: 292-302 e1.
115. Kirchhof P, Breithardt G, Aliot E et al. Personalized management of atrial fibrillation: proceedings from the fourth Atrial Fibrillation competence NETwork/European Heart Rhythm Association consensus conference. Europace 2013; 15: 1540-56.
116. Camm AJ, Savelieva I. Stroke risk stratification in patients with atrial fibrillation: Comme ci, comme ça, plus ça change. J Am Coll Cardiol 2015; 66: 1860-3.
117. Schotten U, Hatem S, Ravens U et al. The European Network for Translational Research in Atrial Fibrillation (EUTRAF): objectives and initial results. Europace 2015; 17: 1457-66.